The climacteric is the years-long biological transition during which a woman’s ovaries gradually wind down their reproductive function, ultimately ending in menopause and the years that follow it. Menopause itself is a single point in time, defined as twelve consecutive months without a period, but the climacteric is the whole arc: the hormonal shifts that begin while cycles are still regular, the increasingly erratic periods, and the continued changes in body and brain long after bleeding has stopped. The process typically spans a decade or more, driven primarily by a shrinking pool of ovarian follicles that alters the hormonal signals between the ovaries and the brain.
How Climacteric Differs from Menopause
People often use “menopause” as shorthand for the entire transition, but clinically the two terms describe different things. Menopause is a retrospective diagnosis: you only know your final menstrual period was final after a full year without another one. The climacteric, by contrast, encompasses everything from the earliest detectable hormonal shifts in the late reproductive years through the stabilization of a new hormonal baseline well into the postmenopausal phase. Think of menopause as a single mile marker on a much longer road.
The age-related decrease in follicle numbers is the engine behind all of it. As the follicle pool shrinks, the ovaries produce less of the hormones that normally keep the brain’s signaling in check, and the pituitary gland responds by ramping up follicle-stimulating hormone (FSH) in an attempt to coax the ovaries into working harder. That tug-of-war between a fading ovary and an increasingly insistent pituitary is what produces the irregular cycles, the hot flashes, and the downstream metabolic changes that define the climacteric experience.1Endocrine Reviews. Ovarian Aging: Mechanisms and Clinical Consequences
The Stages, Mapped Out
Researchers developed a staging system called STRAW+10 to give clinicians and women a shared vocabulary for where they are in the process. It divides the adult female reproductive lifespan into three broad phases, broken into seven numbered stages that count backward and forward from the final menstrual period (Stage 0).2PubMed Central. EXECUTIVE SUMMARY of STRAW+10: Addressing the Unfinished Agenda of Staging Reproductive Aging
- Late reproductive (Stage −3): Cycles are still regular but FSH levels start creeping upward. Most women would not notice anything different yet.
- Early menopausal transition (Stage −2): Cycle length becomes variable, sometimes shorter, sometimes longer. FSH is clearly elevated.
- Late menopausal transition (Stage −1): Periods start being skipped altogether, with gaps of 60 days or more. FSH continues rising.
- Early postmenopause (Stages +1a, +1b, +1c): The first several years after the final period. Vasomotor symptoms tend to peak during this window.
- Late postmenopause (Stage +2): Hormone levels have largely stabilized at their new baseline. Symptoms like hot flashes may have eased, but other changes, such as bone density loss and genital tissue thinning, continue.
Hormone tracking across these stages shows that estradiol drops relatively steadily from Stage −2 all the way through early postmenopause, while FSH rises quickly and then levels off soon after the final period, remaining elevated for at least two decades.3PubMed. Follicle stimulating hormone and estradiol trajectories from menopausal transition to late postmenopause in indigenous Chinese women That mismatch is worth knowing about: just because FSH stabilizes does not mean the body has finished adjusting. Estrogen-sensitive tissues, from vaginal walls to bone to skin, keep responding to falling estradiol levels long after the hormonal drama of the transition itself has quieted.
Why Hot Flashes Happen
Hot flashes are the hallmark symptom of the climacteric, reported by roughly three-quarters of women going through it. For years, the mechanism was poorly understood beyond “estrogen drops and flashes happen.” The picture is now much clearer, thanks to research on a specific cluster of neurons in the brain’s hypothalamus that use three signaling chemicals: kisspeptin, neurokinin B, and dynorphin. These so-called KNDy neurons act as a relay between estrogen levels and the brain’s thermostat.
When estrogen is present in normal premenopausal amounts, it keeps KNDy neurons in check. As estrogen declines during the climacteric, these neurons become overactive, flooding the brain’s temperature-regulation center with neurokinin B. That signal triggers the body’s heat-dissipation response: blood vessels near the skin surface dilate, sweating kicks in, and you feel a sudden wave of heat, even though your core temperature has not meaningfully changed.4PubMed Central. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes Animal studies have confirmed that destroying these neurons reduces the skin blood-vessel dilation that is a cardinal sign of a hot flash.5PubMed Central. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature
Understanding the KNDy pathway matters for a practical reason: it is the basis for a new class of medications. Fezolinetant, the first non-hormonal drug approved specifically for menopausal hot flashes, works by blocking the neurokinin 3 receptor that these overactive neurons rely on.6PubMed. Neurokinin 3 receptor antagonism for menopausal hot flashes In animal models, the drug reduced hot flash-like symptoms in a dose-dependent way without affecting estrogen or FSH levels, meaning it sidesteps the hormonal system entirely.7PubMed. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats For women who cannot or prefer not to take hormone therapy, this represents a genuinely new option, not just another repurposed antidepressant.
How Long Vasomotor Symptoms Last
One of the most frustrating aspects of hot flashes and night sweats is their unpredictability. A longitudinal study that followed women for up to 13 years found that among those who never used hormone therapy, bothersome vasomotor symptoms lasted an average of about five years, with a median of four. The range was wide, though, with a standard deviation of nearly four years, meaning some women were done in a year or two while others dealt with flashes for a decade or longer.8PubMed. Duration of vasomotor symptoms in middle-aged women: a longitudinal study The same study found that regular exercise was the only factor associated with a shorter duration of symptoms. That is not a guarantee, but it is one of the few modifiable factors with any evidence behind it.
Changes That Outlast Hot Flashes
Hot flashes and night sweats get the most attention because they are hard to ignore. But several other climacteric changes are longer lasting and, for many women, ultimately more impactful on daily life.
Genitourinary Changes
The vaginal and urinary-tract tissues are densely packed with estrogen receptors. When estrogen falls, those tissues thin, lose elasticity, and become drier. The vaginal lining becomes more fragile, blood flow to the area decreases, and the chemical environment shifts: less glycogen in vaginal cells means fewer beneficial bacteria and a higher pH, which raises the risk of irritation and infection.9PubMed Central. The Genitourinary Syndrome of Menopause: An Overview of the Recent Data The lower urinary tract is affected as well, with changes to bladder capacity and the urethral lining that can contribute to urgency, frequency, and stress incontinence.
Unlike hot flashes, which tend to peak and then improve over years, these genitourinary changes are progressive. They do not get better on their own with time; they get worse. Vaginal dryness can affect sexual function, daily comfort, and interpersonal relationships in ways that women often underreport and clinicians often underask about.10PubMed Central. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Recent research has reframed this as a broader syndrome spanning not just the vaginal lining but also tissue structure, nerve function, blood vessels, and the vaginal microbiome.11International Journal of Research Publications. Beyond Vaginal Atrophy: A Systematic Review of the Multidimensional Pathophysiology, Phenotypes, and Personalized Management of Genitourinary Syndrome of Menopause
Sleep Disruption
Poor sleep is one of the most common complaints during the climacteric, and it does not always trace back to night sweats. Estrogen supports the body’s internal clock, and its decline weakens the normal circadian rhythm. Melatonin synthesis and secretion can be disrupted, leading to more fragmented sleep even on nights when hot flashes are not the problem.12PubMed Central. Midlife Sleep and Circadian Health: Implications for Cardiovascular and Cognitive Outcomes Some women develop primary insomnia during the transition, a sleep disorder that occurs independently of night sweats or other conditions.13PubMed Central. Sleep Disruption in the Menopausal Transition and Postmenopause: A Narrative Review This distinction matters because treating the insomnia may require different strategies than treating the hot flashes.
Skin and Collagen
Estrogen plays a structural role in skin, helping to maintain collagen, elasticity, and moisture. As levels fall, the skin thins, collagen content drops, and water-retaining molecules in the tissue decrease, leading to dryness, reduced firmness, and slower wound healing.14PubMed Central. Managing Menopausal Skin Changes: A Narrative Review of Skin Quality Changes, Their Aesthetic Impact, and the Actual Role of Hormone Replacement Therapy in Improvement This is not solely an aesthetic concern. Older postmenopausal skin is more vulnerable to cuts, tears, and bruising, and injuries take longer to heal. The strong link between estrogen loss and collagen decline is well documented.15Best Practice & Research Clinical Obstetrics & Gynaecology. Skin connective tissue and ageing
Metabolic and Cardiovascular Shifts
The climacteric reshapes how the body handles fat, sugar, and cholesterol. Even among women whose weight does not change dramatically, the distribution of body fat shifts toward the abdomen. Postmenopausal women, including those at normal weight, tend to carry more visceral fat and less lean muscle mass compared with premenopausal women.16PubMed Central. The Impact of the Menopausal Transition on Body Composition and Abdominal Fat Redistribution These changes come alongside increased insulin resistance and a worsening lipid profile, which together raise the risk of metabolic syndrome.17PubMed Central. Metabolic Disorders in Menopause Standard BMI measurements can underestimate the problem, because the shift is from muscle to visceral fat, which may not register as weight gain on a scale.18PubMed Central. Cardiometabolic Health During the Climacteric Transition: A Narrative Review of Lifestyle, Physiological, and Nutritional Approaches
On the cardiovascular side, the loss of estrogen’s protective effects on blood vessels leads to stiffer arteries, worse endothelial function, and a lipid profile that shifts toward higher cardiovascular risk.19PubMed Central. Cardiovascular Disease Risk in Women with Menopause Inflammation increases, the system that regulates blood pressure becomes more active, and nitric oxide, the molecule that helps blood vessels relax, becomes less available.20Atherosclerosis. Lipid metabolism in women: A review This is why cardiovascular disease risk rises sharply for women after menopause, even if they had low risk before.
Hormone Therapy and the Timing Window
Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms, but the decades-long back-and-forth about its safety has left many women and their doctors confused about when, if ever, it makes sense. The evidence now supports what researchers call a “window of opportunity”: starting hormone therapy before age 60 or within ten years of menopause, and continuing for six or more years, appears to reduce the risk of coronary heart disease and overall mortality while minimizing harms.21PubMed Central. THE WINDOW OF OPPORTUNITY FOR CORONARY HEART DISEASE PREVENTION WITH HORMONE THERAPY: PAST, PRESENT AND FUTURE IN PERSPECTIVE
A meta-analysis of hormone therapy trials found that younger initiators did not appear to be at increased risk of dying or experiencing coronary events, though the risk of stroke and blood clots remained elevated regardless of timing.22IJC Heart & Vasculature. A systematic review and meta-analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke On the cognitive side, observational data suggest that hormone therapy may reduce the risk of Alzheimer’s disease when started around menopause, though the picture is muddied by the fact that combined estrogen-plus-progestin formulations appear to increase risk regardless of timing.23PubMed Central. The Critical Window Hypothesis of Hormone Therapy and Cognition: A Scientific Update on Clinical Studies The type of hormone formulation matters as much as the timing, and this is an area where blanket recommendations do not serve women well.
Do Supplements and Lifestyle Changes Help
Phytoestrogens, the plant-based compounds found in soy, flaxseed, and red clover, are among the most popular non-prescription approaches to climacteric symptoms. The evidence is mixed. A Cochrane review found no conclusive evidence that phytoestrogen supplements reduce the frequency or severity of hot flashes and night sweats, though it noted that concentrated genistein (one specific type of isoflavone) deserved further study.24PubMed Central. Phytoestrogens for menopausal vasomotor symptoms A more recent review painted a rosier picture, reporting that dietary isoflavone intake in the range of 50 to 80 milligrams per day reduced severe hot flashes substantially and improved metabolic markers, with the review emphasizing a combined approach including diet, gut health, and exercise.25PubMed Central. Natural strategies to optimize estrogen levels in aging women: mini review The gap between these conclusions may reflect the difference between isolated supplement pills and a genuinely phytoestrogen-rich diet, or it may reflect differences in study design. Either way, the honest summary is that phytoestrogens from food are probably modestly helpful for some women, while capsules from a shelf are unlikely to be transformative.
Cross-Cultural Differences in Symptom Experience
The climacteric is a universal biological process, but the way it is experienced varies dramatically across populations. Women in African and Asian countries tend to report fewer and less severe hot flashes than women in North America and Europe, while Asian women report higher rates of joint and muscle pain. Within the United States, studies have found that Japanese and Chinese American women report the fewest menopausal symptoms overall, African American women report more vaginal dryness and hot flashes, and Hispanic women report the most symptoms across the board.26PubMed Central. Cultural Determinants of Body Image: What About the Menopausal Transition?
These differences are not purely cultural. Research shows that the variation reflects a combination of underlying biological differences, including diet, body composition, and genetics, and sociocultural factors like attitudes toward aging, the social role of menopausal women, and how willing women are to report symptoms in a medical context.27PubMed. The roles of biologic and nonbiologic factors in cultural differences in vasomotor symptoms measured by surveys In cultures where menopause is seen as a natural transition or even a social promotion (freedom from menstruation, elevated family status), women consistently report less distress. In cultures where it is framed as decline or loss, the opposite holds. The fact that some populations report very few hot flashes despite the same underlying hormonal changes suggests that biology sets the stage, but culture and context shape the performance in meaningful ways.28PubMed. Cultural significance and physiological manifestations of menopause. A biocultural analysis
Is There a Male Climacteric
The term “male menopause” or “andropause” gets thrown around casually, but the comparison is misleading. In women, the climacteric is driven by a near-complete shutdown of the ovaries over a defined period. In men, testosterone declines gradually, roughly one to two percent per year starting in the thirties, but the testes never stop producing it entirely. There is no male equivalent of the final menstrual period, no dramatic hormonal cliff, and no universal set of symptoms that most men experience at a predictable age. The testosterone decline in aging men also overlaps substantially with other conditions, including depression, obesity, and chronic illness, making it hard to separate “low testosterone from aging” from “low testosterone because of something else.”29PubMed. Age-associated testosterone decline in men: clinical issues for psychiatry Some men do experience symptoms that improve with testosterone replacement, but this is a different phenomenon from the climacteric: it is selective, gradual, and not inevitable.
Why Menopause Exists at All
From an evolutionary standpoint, menopause is strange. Most mammals remain fertile until they die. Humans, along with a handful of whale species, are among the very few animals that live for decades after reproduction stops. The leading explanation for why this happened is the grandmother hypothesis: once early human females began sharing food with their grandchildren, older women who had stopped bearing their own children could boost the survival of existing descendants, which was a more effective way to pass on genes than continuing to have babies at increasing personal risk.30PubMed Central. Grandmothering, menopause, and the evolution of human life histories
This hypothesis connects several otherwise puzzling features of human biology: our unusually long lifespan relative to body size, our late age at maturity, the fact that we wean children long before they can feed themselves, and the existence of menopause itself. If grandmothering was valuable enough to drive selection, then evolution would have slowed down the aging of everything except the ovaries, because the grandmother’s body needed to remain functional for decades after she stopped reproducing.31PubMed. Grandmothers and the evolution of human longevity The data comparing modern human fertility decline with that of chimpanzees are consistent with this idea: the rate at which fertility drops with age looks similar in both species, but humans tacked on decades of post-reproductive life that chimps never evolved. The climacteric, in this light, is not a malfunction. It is one half of an evolutionary bargain, the ovaries shut down on schedule so the rest of the body can keep going in a role that no longer requires them.